ROCKVILLE, Md., Nov. 7, 2023 /PRNewswire/ REGENXBIO Inc. today announced it will participate the following upcoming investor conferences:
Stifel 2023 Healthcare Conference Fireside Chat Date:.
REGENXBIO to Participate in Upcoming Investor Conferences lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
ABBV-RGX-314 continues to be well tolerated in 50 patients from dose levels 1 and 2 (Cohorts 1-3) with no drug-related serious adverse events Dose level 2.
ROCKVILLE, Md., Nov. 1, 2023 /PRNewswire/ REGENXBIO Inc. today announced that it will host a conference call on Wednesday, November 8, 2023, at 4:30 p.m. EST to discuss its financial results for.